Skip to content

Topical mupirocin reduces Lupus inflammation

Systemic lupus erythematosus, more commonly known as lupus, has a variety of symptoms and margin of improvement when it comes to treatment.

Cutaneous lupus erythematosus is a common manifestation of systemic lupus erythematosus.

The condition is characterized by rashes in various parts of the body, including the scalp, hair loss and skin scars.

The rashes are caused by the inflammation of the immune system that fights the body.

Standard treatment for cutaneous lupus erythematosus is the use of immunosuppressants and biological drugs to reduce inflammation.

While medications can be useful, many patients with systemic lupus erythematosus already take a lot of medications and look for other treatment methods other than pills.

J. Michelle Kahlenberg, MD, Ph.D., Professor of Internal Medicine in the Rheumatology Division of the University of Michigan Health, directed a team of researchers who were looking for one of these alternatives, a current treatment called Mipirocina.

This test was based on the previous discovery of Kahlenberg that the eruptions of cutaneous lupus are often colonized with a bacterium of the common skin, areus staphylocos, also known in Pantefio., and contributes to inflammation in eruptions.

Mugirocin kills this type of bacteria.

The study randomly selected patients with systemic lupus erythematosus who are currently experiencing lupus erythematous skin flares to treat their skin lesions with mupirocin or with inactive control, gasolatum jelly.

Samples of the nose and injury skin were used to determine the abundance of the baseline and after the treatment of abundance of abundance and the profiles of the microbial community.

The matched samples collected before treatment with the topical solution and seven days after the treatment showed decreases in the staphylococcus samples aureusin of lesion staphylococcus, the samples treated with mupirocin.

It is important to highlight that the reduction in the Staph was also accompanied by a reduction in inflammatory signals, including gene expression driven by the interferon, in injuries.

“In addition to decreasing inflammation by decreasing the staphylococcus aureus, the treatment with mupirocina also reduced the levels of skin monocytes, which are important to boost cutaneous lupus,” said Kahlenberg.

Mipirocin is a recipe treatment, and although this early study showed signs of inflammation decrease, the study was not designed to see if the eruption of the cutaneous lupus erythematosus can decrease.

“Additional larger studies are needed to determine if topical antibiotics will be useful for eruptions to disappear,” Kahlenberg said.

“However, this is an exciting first step to demonstrate that there may be additional treatments that can improve inflammation beyond our usual immunosuppressive and biological medications.”

Leave a Reply

Your email address will not be published. Required fields are marked *